Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6ZG9

Structure of M1-StaR-T4L in complex with GSK1034702 at 2.5A

Summary for 6ZG9
Entry DOI10.2210/pdb6zg9/pdb
DescriptorMuscarinic acetylcholine receptor M1,Endolysin,Muscarinic acetylcholine receptor M1, 7-fluoranyl-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1~{H}-benzimidazol-2-one, 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID, ... (6 entities in total)
Functional Keywordsgpcr, 7tm, membrane protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains1
Total formula weight54194.86
Authors
Rucktooa, P.,Cooke, R.M. (deposition date: 2020-06-18, release date: 2021-10-06, Last modification date: 2024-10-23)
Primary citationBrown, A.J.H.,Bradley, S.J.,Marshall, F.H.,Brown, G.A.,Bennett, K.A.,Brown, J.,Cansfield, J.E.,Cross, D.M.,de Graaf, C.,Hudson, B.D.,Dwomoh, L.,Dias, J.M.,Errey, J.C.,Hurrell, E.,Liptrot, J.,Mattedi, G.,Molloy, C.,Nathan, P.J.,Okrasa, K.,Osborne, G.,Patel, J.C.,Pickworth, M.,Robertson, N.,Shahabi, S.,Bundgaard, C.,Phillips, K.,Broad, L.M.,Goonawardena, A.V.,Morairty, S.R.,Browning, M.,Perini, F.,Dawson, G.R.,Deakin, J.F.W.,Smith, R.T.,Sexton, P.M.,Warneck, J.,Vinson, M.,Tasker, T.,Tehan, B.G.,Teobald, B.,Christopoulos, A.,Langmead, C.J.,Jazayeri, A.,Cooke, R.M.,Rucktooa, P.,Congreve, M.S.,Weir, M.,Tobin, A.B.
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Cell, 184:5886-, 2021
Cited by
PubMed Abstract: Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative approach is to directly activate cholinergic receptors responsible for learning and memory. The M1-muscarinic acetylcholine (M1) receptor is the target of choice but has been hampered by adverse effects. Here we aimed to design the drug properties needed for a well-tolerated M1-agonist with the potential to alleviate cognitive loss by taking a stepwise translational approach from atomic structure, cell/tissue-based assays, evaluation in preclinical species, clinical safety testing, and finally establishing activity in memory centers in humans. Through this approach, we rationally designed the optimal properties, including selectivity and partial agonism, into HTL9936-a potential candidate for the treatment of memory loss in Alzheimer's disease. More broadly, this demonstrates a strategy for targeting difficult GPCR targets from structure to clinic.
PubMed: 34822784
DOI: 10.1016/j.cell.2021.11.001
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.5 Å)
Structure validation

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon